Poster Presentations 2017
DOI: 10.1136/annrheumdis-2017-eular.3048 View full text |Buy / Rent full text
|
|

Abstract: BackgroundTofacinitib is an oral Janus Kinase for the treatment for rheumatoid arthritis (RA). The efficacy and safety of tofacitinib in monotherapy or in combination with other DMARDs has been demonstrated in clinical trials. However previous studies had report hematological changes and infections associated to the use of this medication (1, 2); in the European Union (EU) Tofacitinib is an investigational medicine and has not been approved for use because concernings regarding its safety.ObjectivesWe aim to d… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles